Automated feature learning and survival prognostication in grade 4 glioma using supervised machine learning models [0.03%]
Yuncong Mao,Linda Tang,Melanie Alfonzo Horowitz et al.
Yuncong Mao et al.
Predicting survival outcomes remains challenging due to the tumor's heterogeneity and the influence of multiple clinical factors. Machine learning (ML) techniques have demonstrated superior predictive performance compared to traditional statistical models.
Prognostic significance of the pretreatment controlling nutritional status score in colorectal cancer patients: an updated meta-analysis with 24 cohort studies [0.03%]
术前营养状况评分对结直肠癌患者预后影响的meta分析研究
Jingkun Shang,Jinlai Wei
Jingkun Shang
Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for survival outcomes were either extracted or calculated. A random-effects model was applied to pool all of the results.
The importance of maximal TURBT in trimodality therapy for muscle-invasive bladder cancer (MIBC) [0.03%]
经尿道膀胱肿瘤电切(TURBT)联合三联疗法治疗肌层浸润性膀胱癌的意义
Chris Ho-Ming Wong,Ivan Ching-Ho Ko,David Ka-Wai Leung et al.
Chris Ho-Ming Wong et al.
This review examines the importance of maximal TURBT in optimizing oncological outcomes in TMT, discusses its technical nuances, and explores the evidence supporting its role in achieving durable local control and improving survival outcomes in MIBC.
Rapid-Onset Myositis and Myocarditis Following Dual Immune Checkpoint Inhibitor Therapy With Nivolumab and Ipilimumab for Gastric Adenocarcinoma: A Case Report [0.03%]
信迪利单抗和贝伐珠单抗联合用药治疗胃癌的免疫相关不良反应：1例爆发性肌炎和心肌炎的病例报告
Steven B Barker,Adeoluwa Adewuyi
Steven B Barker
Immune checkpoint inhibitors (ICIs) have revolutionized oncology by improving survival outcomes with fewer side effects than traditional chemotherapy.
Case Reports
Cureus. 2025 May 14;17(5):e84121. DOI:10.7759/cureus.84121 2025
Comparison of Efficacy and Safety of Endoscopic Breast-Conserving Surgery Versus Conventional Breast-Conserving Surgery in Elderly Patients With Breast Cancer: Insights From a Single-Center Retrospective Analysis [0.03%]
内镜下保留乳房手术与传统保留乳房手术治疗老年乳腺癌患者的疗效及安全性比较：单中心回顾性分析的启示
Wei Zhang,Jundan Wang,Yun Xiong et al.
Wei Zhang et al.
No significant differences were observed in perioperative immune cell markers, adipokine levels, or survival outcomes between the groups.
Comparative Study
Annali italiani di chirurgia. 2025;96(6):759-770. DOI:10.62713/aic.3989 2025
Manon Wick,Chloé Denis,Pierre Frères et al.
Manon Wick et al.
Both combinations have demonstrated superior survival outcomes compared to sunitinib, the previous standard of care until 2019.
Guideline
Revue medicale de Liege. 2025 May;80(5-6):323-329. DOI: 2025
Targeted inhibition of Ninjurin2 promotes chemosensitivity in chemoresistant gastric cancer by suppressing cancer-initiating cells [0.03%]
Ninjurin2靶向抑制通过抑制癌症起始细胞促进化学抗性胃癌的化疗敏感性
Hyo Shik Shin,Jae-Il Choi,Hye Won Chung et al.
Hyo Shik Shin et al.
Clinical analysis showed that high NINJURIN2 expression correlated with poor survival outcomes in gastric cancer patients.
Analysis of Demographic Associations and Survival Outcomes in Patients With Colorectal Cancer at a Tertiary Care Hospital in Pakistan. A Retrospective Cross-Sectional Study [0.03%]
巴基斯坦一家三级护理医院结直肠癌患者的 demographics 状况及生存结局分析：一项回顾性横断面研究
Muhammad Osama,Hira Moosa,Hussain Sohail Rangwala et al.
Muhammad Osama et al.
IntroductionColorectal cancer (CRC) is the third most common cancer worldwide, with higher rates in industrialized countries. By 2030, the number of CRC cases may rise by 60%, reaching 2.2 million new cases and 1.1 million deaths. In 2020, ...
Comparison of Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib with First- and Second-Generation TKIs for Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Systematic Review and Bias-Corrected Meta-analysis [0.03%]
ponatinib与首代和二代酪氨酸激酶抑制剂治疗费城染色体阳性急性淋巴细胞白血病的比较：系统评价和偏倚修正 meta 分析
Muhammad Zain Raza,Huzaifa Fayyaz Khwaja,Hafiz Muhammad Ehsan Arshad et al.
Muhammad Zain Raza et al.
Conclusion: Ponatinib is associated with significantly better survival outcomes compared to other TKIs.
Multiple Myeloma Unpacked [0.03%]
解读多发性骨髓瘤
Francesca Gay,Edoardo Marchetti,Giuseppe Bertuglia
Francesca Gay
The current treatment landscape for multiple myeloma involves a combination of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and autologous stem cell transplantation, which have significantly improved survival outcomes in recent years.
耗时 0.25196 秒，为您在
48229835
条记录里面共找到 10000 篇文章 [XML]